Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):207–210. doi: 10.1097/QAI.0b013e3182253c19

Table 2.

The cost effectiveness of the use of a vaginal microbicide at low and high coverage. Numbers in brackets are 95% confidence limits. The cost per infection not-averted is the estimated cost of keeping a person on ART for 23 years.14

Coverage US$/infection averted US$/infection not-averted US$/DALY saved US$ Gross National Income
25% 2,392 (1,830) 8,396 104 (77) 5,770
90% 1,701 (1,281) 74 (56)